Shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) saw strong trading volume on Thursday . 1,280,050 shares changed hands during mid-day trading, an increase of 210% from the previous session’s volume of 413,502 shares.The stock last traded at $2.87 and had previously closed at $2.66.
Several research analysts have recently commented on PIRS shares. ValuEngine downgraded Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. HC Wainwright set a $5.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. BidaskClub downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 26th. Finally, Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.00.
The company has a market capitalization of $144.04 million, a P/E ratio of -7.18 and a beta of 1.98.
Hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $110,000. Rhumbline Advisers boosted its stake in Pieris Pharmaceuticals by 51.5% in the 4th quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 22,720 shares during the period. California Public Employees Retirement System bought a new stake in Pieris Pharmaceuticals in the 2nd quarter valued at $179,000. Trexquant Investment LP boosted its stake in Pieris Pharmaceuticals by 119.7% in the 3rd quarter. Trexquant Investment LP now owns 48,971 shares of the biotechnology company’s stock valued at $274,000 after purchasing an additional 26,680 shares during the period. Finally, Unterberg Capital LLC bought a new stake in Pieris Pharmaceuticals in the 3rd quarter valued at $308,000. Institutional investors own 65.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals (PIRS) Sees Unusually-High Trading Volume” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4116286/pieris-pharmaceuticals-pirs-sees-unusually-high-trading-volume.html.
Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.